A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16141 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Jeyalakshmi Kandhavelu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Colonic Neoplasms, Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, PT National Funds, South African Medical Research Council.
Abstract (Originalsprache)
Background and Purpose Colorectal cancer (CRC) is the second most lethal disease, with high mortality due to its heterogeneity and chemo‐resistance. Here, we have focused on the epidermal growth factor receptor (EGFR) as an effective therapeutic target in CRC and studied the effects of polyphenols known to modulate several key signalling mechanisms including EGFR signalling, associated with anti‐proliferative and anti‐metastatic properties. Experimental Approach Using ligand‐ and structure‐based cheminformatics, we developed three potent, selective alkylaminophenols, 2‐[(3,4‐dihydroquinolin‐1(2 H )‐yl)( p ‐tolyl)methyl]phenol (THTMP), 2‐[(1,2,3,4‐tetrahydroquinolin‐1‐yl)(4‐methoxyphenyl)methyl]phenol (THMPP) and N ‐[2‐hydroxy‐5‐nitrophenyl(4′‐methylphenyl)methyl]indoline (HNPMI). These alkylaminophenols were assessed for EGFR interaction, EGFR‐pathway modulation, cytotoxic and apoptosis induction, caspase activation and transcriptional and translational regulation. The lead compound HNPMI was evaluated in mice bearing xenografts of CRC cells. Key Results Of the three alkylaminophenols tested, HNPMI exhibited the lowest IC 50 in CRC cells and potential cytotoxic effects on other tumour cells. Modulation of EGFR pathway down‐regulated protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. Cell cycle analysis revealed that HNPMI induced G0/G1 phase arrest in CRC cells. HNPMI altered the mRNA for and protein levels of several apoptosis‐related proteins including caspase 3, BCL‐2 and p53. HNPMI down‐regulated the proteins crucial to oncogenesis in CRC cells. Assays in mice bearing CRC xenografts showed that HNPMI reduced the relative tumour volume. Conclusions and Implications HNPMI is a promising EGFR inhibitor for clinical translation. HNPMI regulated apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in CRC cell lines, showing potential as a therapeutic agent in the treatment of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Molecular Signalling Lab, Faculty of Medicine and Health Technology, BioMediTech, Tampere University and Tays Cancer Centre, Tampere, Finland.
- BioMediTech Institute and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Science Center, Tampere University Hospital, Tampere, Finland.
- Research and Publication Wing, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
- Department of Physiology, Acibadem University School of Medicine, Atasehir, Istanbul, Turkey.
ORCID-Profile: Saravanan Konda Mani, Meenakshisundaram Kandhavelu
Förderung
- Fundação para a Ciência e a Tecnologia
- PT National Funds
- South African Medical Research Council
Zitieren
APA
Kandhavelu, J., Subramanian, K., Naidoo, V., Sebastianelli, G., Doan, P., Konda Mani, S., Yapislar, H., Haciosmanoglu, E., Arslan, L., Ozer, S., Thiyagarajan, R., Candeias, N. R., Penny, C., Kandhavelu, M., & Murugesan, A. (2024). A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16141
Vancouver
Kandhavelu J, Subramanian K, Naidoo V, Sebastianelli G, Doan P, Konda Mani S, et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer. British Journal of Pharmacology. 2024. doi:10.1111/bph.16141
BibTeX
@article{Kandhavelu2024,
author = {Kandhavelu, Jeyalakshmi and Subramanian, Kumar and Naidoo, Vivash and Sebastianelli, Giulia and Doan, Phuong and Konda Mani, Saravanan and Yapislar, Hande and Haciosmanoglu, Ebru and Arslan, Leman and Ozer, Samed and Thiyagarajan, Ramesh and Candeias, Nuno R and Penny, Clement and Kandhavelu, Meenakshisundaram and Murugesan, Akshaya},
title = {A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16141}
}
EUVIMED